AR049512A1 - Derivados de tetrahidrofurano tetraciclicos. composiciones farmaceuticas - Google Patents
Derivados de tetrahidrofurano tetraciclicos. composiciones farmaceuticasInfo
- Publication number
- AR049512A1 AR049512A1 ARP050102402A ARP050102402A AR049512A1 AR 049512 A1 AR049512 A1 AR 049512A1 AR P050102402 A ARP050102402 A AR P050102402A AR P050102402 A ARP050102402 A AR P050102402A AR 049512 A1 AR049512 A1 AR 049512A1
- Authority
- AR
- Argentina
- Prior art keywords
- alkyl
- aryl
- halomethyl
- hydroxy
- group
- Prior art date
Links
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical class C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 title abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 2
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 abstract 11
- 125000003118 aryl group Chemical group 0.000 abstract 7
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 7
- 125000004970 halomethyl group Chemical group 0.000 abstract 6
- 125000004356 hydroxy functional group Chemical group O* 0.000 abstract 6
- 125000003545 alkoxy group Chemical group 0.000 abstract 5
- 125000004453 alkoxycarbonyl group Chemical group 0.000 abstract 5
- 125000004916 (C1-C6) alkylcarbonyl group Chemical group 0.000 abstract 4
- 125000004397 aminosulfonyl group Chemical group NS(=O)(=O)* 0.000 abstract 4
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 abstract 4
- 125000001475 halogen functional group Chemical group 0.000 abstract 4
- 125000004093 cyano group Chemical group *C#N 0.000 abstract 3
- 125000006619 (C1-C6) dialkylamino group Chemical group 0.000 abstract 2
- 125000003806 alkyl carbonyl amino group Chemical group 0.000 abstract 2
- 125000005196 alkyl carbonyloxy group Chemical group 0.000 abstract 2
- 125000000217 alkyl group Chemical group 0.000 abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 2
- 229910052739 hydrogen Inorganic materials 0.000 abstract 2
- 239000001257 hydrogen Substances 0.000 abstract 2
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 abstract 2
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 2
- QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 abstract 2
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 abstract 1
- 125000000815 N-oxide group Chemical group 0.000 abstract 1
- 208000012902 Nervous system disease Diseases 0.000 abstract 1
- 208000025966 Neurological disease Diseases 0.000 abstract 1
- 239000002253 acid Substances 0.000 abstract 1
- 125000004390 alkyl sulfonyl group Chemical group 0.000 abstract 1
- 125000005129 aryl carbonyl group Chemical group 0.000 abstract 1
- 229910052799 carbon Inorganic materials 0.000 abstract 1
- 125000004432 carbon atom Chemical group C* 0.000 abstract 1
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 abstract 1
- 230000005764 inhibitory process Effects 0.000 abstract 1
- HZVOZRGWRWCICA-UHFFFAOYSA-N methanediyl Chemical compound [CH2] HZVOZRGWRWCICA-UHFFFAOYSA-N 0.000 abstract 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 abstract 1
- 125000002757 morpholinyl group Chemical group 0.000 abstract 1
- 229910052757 nitrogen Inorganic materials 0.000 abstract 1
- 125000004433 nitrogen atom Chemical group N* 0.000 abstract 1
- 230000000966 norepinephrine reuptake Effects 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
- 239000000651 prodrug Substances 0.000 abstract 1
- 229940002612 prodrug Drugs 0.000 abstract 1
- 208000020016 psychiatric disease Diseases 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 229940076279 serotonin Drugs 0.000 abstract 1
- 125000001424 substituent group Chemical group 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D307/93—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems condensed with a ring other than six-membered
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Psychiatry (AREA)
- Addiction (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Pain & Pain Management (AREA)
- Child & Adolescent Psychology (AREA)
- Obesity (AREA)
- Psychology (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Furan Compounds (AREA)
Abstract
Los compuestos pertenecen a la categoría de derivados de tetrahidrofurano condensados utilizados para prevencion y tratamiento de trastornos psiquiátricos y neurologicos por su afinidad de union hacia receptores de serotonina, dopamima y con propiedades de inhibicion de la recaptacion de norepinefrina. Composiciones farmacéuticas que los contienen. Reivindicacion 1: Un compuesto de formula (1), su sal de adicion de ácido o de base farmacéuticamente aceptable, su forma estereoquímicamente isomérica, su forma de N-oxido y su profármaco, donde: n es un numero entero igual a 0,1, 2, 3, 4, 5 o 6; p es un numero entero igual a 0, 1, 2, 3 o 4; q es un numero entero igual a 0, 1, 2, 3 o 4; r es un numero entero igual a 0, 1, 2, 3, 4 o 5; R1 y R2 cada uno se selecciona, independientemente, del grupo de hidrogeno; alquilo C1-6; alquil C1-6-carbonilo; halometilcarbonilo; arilo; alquilsulfonilo y alquilo C1-6 sustituido con hidroxi, alquiloxi C1-6, carboxilo, alquil C1-6 carboniloxi, alquiloxi C1-6 carbonilo o arilo; o R1 y R2 en forma conjunta con el átomo de nitrogeno al cual están unidos pueden formar un anillo morfolinilo o un radical del grupo de formulas (2), donde: R9, R10, R11 y R12 cada uno independientemente se selecciona del grupo de hidrogeno; halo; halometilo y alquilo C1-6; m es un numero entero igual a 0, 1, 2, o 3; R13, R14, R15 y R16 cada uno se selecciona independientemente del grupo de hidrogeno; alquilo C1-6; arilo y arilcarbonilo; o R15 y R16 en forma conjunta pueden formar un radical bivalente alcanodiilo C4-5; R17 se selecciona del grupo de hidrogeno; alquilo C1-6; alquil C1-6 carbonilo; halometilcarbonilo; alquiloxi C1-6 carbonilo; arilo; di(aril) metilo; alquilo C1-6 sustituido con hidroxi, alquiloxi C1-6, carboxilo, alquil C1-6 carboniloxi, alquiloxi C1-6 carbonilo y arilo; cada R3 se selecciona, independientemente, del grupo de hidrogeno; halo; ciano; hidroxi; halometilo; halometoxi; carboxilo; nitro; amino; mono- o di(alquil C1-6) amino; alquil C1-6 carbonilamino; aminosulfonilo; mono- o di(alquil C1-6) aminosulfonilo; alquilo C1-6; alquiloxi C1-6; alquil C1-6 carbonilo y alquiloxi C1-6 carbonilo; cada R4 se selecciona, independientemente, del grupo de hidrogeno; halo; ciano; hidroxi; halometilo; halometoxi; carboxilo; nitro; amino; mono- o di(alquil C1-6) amino; alquil C1-6 carbonilamino; aminosulfonilo; mono- o di(alquil C1-6) aminosulfonilo; alquilo C1-6; alquiloxi C1-6; alquil C1-6 carbonilo y alquiloxi C1-6 carbonilo; cada R5 se selecciona, independientemente, del grupo de alquilo C1-6; ciano y halometilo; R6 y R7 cada uno, independientemente del otro, se selecciona del grupo de hidrogeno, hidroxi, alquilo C1-6, halometilo y alquiloxi C1-6; con la condicion de que R6 y R7 no sean simultáneamente hidrogeno; o R6 y R7 tomados en forma conjunta puedan formar un radical metileno (=CH2); o, junto con el átomo de carbono al cual están unidos, un carbonilo; y arilo es fenilo; o fenilo sustituido con 1, 2 o 3 sustituyentes seleccionados del grupo de halo, hidroxi, alquilo C1-6 y halometilo.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP2004051105 | 2004-06-14 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR049512A1 true AR049512A1 (es) | 2006-08-09 |
Family
ID=34957878
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP050102402A AR049512A1 (es) | 2004-06-14 | 2005-06-13 | Derivados de tetrahidrofurano tetraciclicos. composiciones farmaceuticas |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US20070197525A1 (es) |
| EP (1) | EP1761514B1 (es) |
| JP (1) | JP2008502649A (es) |
| CN (1) | CN1968942B (es) |
| AR (1) | AR049512A1 (es) |
| AT (1) | ATE402932T1 (es) |
| AU (1) | AU2005251948A1 (es) |
| CA (1) | CA2567847A1 (es) |
| DE (1) | DE602005008596D1 (es) |
| DK (1) | DK1761514T3 (es) |
| ES (1) | ES2311228T3 (es) |
| PL (1) | PL1761514T3 (es) |
| PT (1) | PT1761514E (es) |
| TW (1) | TW200612899A (es) |
| WO (1) | WO2005121113A1 (es) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20090023721A1 (en) * | 2005-05-26 | 2009-01-22 | Megens Antonius Adrianus Hendr | Novel Substituted Tetracyclic Tetrahydrofuran, Pyrrolidine and Tetrahydrothiophene Derivatives and Their Use as a Medicament |
| WO2007132841A1 (ja) | 2006-05-16 | 2007-11-22 | Takeda Pharmaceutical Company Limited | 縮合複素環化合物およびその用途 |
| WO2009063992A1 (ja) | 2007-11-15 | 2009-05-22 | Takeda Pharmaceutical Company Limited | 縮合ピリジン誘導体およびその用途 |
| MX388038B (es) | 2008-12-19 | 2025-03-19 | Supernus Pharmaceuticals Inc | Uso de molindona para el tratamiento de agresión. |
| ES2756711T3 (es) | 2010-03-31 | 2020-04-27 | Supernus Pharmaceuticals Inc | Formulaciones estabilizadas de compuestos del SNC |
| KR20140051998A (ko) * | 2011-08-03 | 2014-05-02 | 교와 핫꼬 기린 가부시키가이샤 | 디벤조옥세핀 유도체 |
| WO2013189920A1 (en) | 2012-06-19 | 2013-12-27 | Ucb Pharma S.A. | New compound based on cinchona alkaloïds for use in asymmetric michael addition |
| JPWO2019131902A1 (ja) | 2017-12-27 | 2020-12-10 | 武田薬品工業株式会社 | 腹圧性尿失禁および便失禁の治療薬 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3565956A (en) * | 1964-10-16 | 1971-02-23 | Sterling Drug Inc | Amino-lower-alkoxy-5-alkylidene-dibenzo(a,d)cycloheptenes |
| US3350405A (en) * | 1964-10-16 | 1967-10-31 | Sterling Drug Inc | Amino-lower-alkoxy-dibenzo [a, d] cyclohepten-5-ones and 10, 11-dihydro derivatives thereof |
| US3562331A (en) * | 1964-10-16 | 1971-02-09 | Sterling Drug Inc | Amino-lower-alkoxy-dibenzo(a,d)cycloheptene-5-carbinols |
| US3507920A (en) * | 1964-10-16 | 1970-04-21 | Sterling Drug Inc | Hydroxydibenzo(a,d)cyclohepten-5-ones and esters and ethers thereof |
| US3812119A (en) * | 1969-11-21 | 1974-05-21 | Ciba Geigy Corp | Dibenzocycloheptenes |
| EA001002B1 (ru) * | 1996-04-12 | 2000-08-28 | Жансен Фармасетика Н.В. | Замещенные тетрациклические производные тетрагидрофурана |
| UA52778C2 (uk) * | 1997-10-10 | 2003-01-15 | Янссен Фармацевтика Н.В. | Галогенозаміщені тетрациклічні похідні тетрагідрофурану, спосіб їх отримання та композиція на їх основі |
| ES2242076T3 (es) * | 2001-12-07 | 2005-11-01 | Janssen Pharmaceutica N.V. | Preparacion de derivados de 3,3a,8,12b-tetrahidro-2h-dibenzo(3,4:6,7)ciclohepta(1,2-b)furano condensados en trans. |
-
2005
- 2005-06-13 JP JP2007515942A patent/JP2008502649A/ja active Pending
- 2005-06-13 EP EP05752829A patent/EP1761514B1/en not_active Expired - Lifetime
- 2005-06-13 WO PCT/EP2005/052706 patent/WO2005121113A1/en not_active Ceased
- 2005-06-13 PT PT05752829T patent/PT1761514E/pt unknown
- 2005-06-13 DE DE602005008596T patent/DE602005008596D1/de not_active Expired - Lifetime
- 2005-06-13 TW TW094119426A patent/TW200612899A/zh unknown
- 2005-06-13 AT AT05752829T patent/ATE402932T1/de active
- 2005-06-13 CN CN2005800194190A patent/CN1968942B/zh not_active Expired - Fee Related
- 2005-06-13 ES ES05752829T patent/ES2311228T3/es not_active Expired - Lifetime
- 2005-06-13 US US11/570,433 patent/US20070197525A1/en not_active Abandoned
- 2005-06-13 CA CA002567847A patent/CA2567847A1/en not_active Abandoned
- 2005-06-13 AR ARP050102402A patent/AR049512A1/es not_active Application Discontinuation
- 2005-06-13 PL PL05752829T patent/PL1761514T3/pl unknown
- 2005-06-13 DK DK05752829T patent/DK1761514T3/da active
- 2005-06-13 AU AU2005251948A patent/AU2005251948A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| PL1761514T3 (pl) | 2009-01-30 |
| ES2311228T3 (es) | 2009-02-01 |
| JP2008502649A (ja) | 2008-01-31 |
| EP1761514B1 (en) | 2008-07-30 |
| WO2005121113A1 (en) | 2005-12-22 |
| CN1968942A (zh) | 2007-05-23 |
| EP1761514A1 (en) | 2007-03-14 |
| CA2567847A1 (en) | 2005-12-22 |
| TW200612899A (en) | 2006-05-01 |
| DK1761514T3 (da) | 2008-12-01 |
| CN1968942B (zh) | 2011-06-15 |
| AU2005251948A1 (en) | 2005-12-22 |
| US20070197525A1 (en) | 2007-08-23 |
| PT1761514E (pt) | 2008-10-28 |
| ATE402932T1 (de) | 2008-08-15 |
| DE602005008596D1 (de) | 2008-09-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR045386A1 (es) | [1,8] naftiridin-2-onas y compuestos relacionados para el tratamiento de la esquizofrenia | |
| AR065622A1 (es) | Derivados de 3-ciano -4- (4-fenil- piperidin -1- il) piridin -2- ona | |
| AR071314A1 (es) | Antagonistas de receptor de cgrp | |
| AR062050A1 (es) | Derivados de amina utiles como agentes anti-cancerigenos | |
| PH12012501773A1 (en) | Arylethynyl derivatives | |
| AR066881A1 (es) | Derivados de oxadiazol, una composicion farmaceutica que los comprende y su uso en la preparacion de medicamentos para el tratamiento de trastornos asociados con la disfuncion del glutamato. | |
| AR041566A1 (es) | Derivados de indol utiles para el tratamiento de enfermedades | |
| AR044475A1 (es) | Derivados de 2-amino -piridina utiles para el tratamiento de enfermedades | |
| AR066120A1 (es) | Derivados de pirimidinona y sus metodos de uso | |
| AR035759A1 (es) | Compuestos acilurea antagonistas de la funcion mpc-1, un procedimiento para su preparacion, composicion farmaceutica y el uso de dichos compuestos para la preparacion de medicamentos | |
| AR115920A1 (es) | Inhibidores tipo indol y azaindol de enzimas pad | |
| AR078638A1 (es) | Antagonistas del receptor de cgrp | |
| AR065015A1 (es) | Derivados de antranilamida, composiciones farmaceuticas que los contienen, y usos para el tratamiento del cancer | |
| AR078542A1 (es) | Moduladores de gpr40 de pirrolidina | |
| WO2008101935A3 (fr) | Nouveaux composés dérivés d'indole et compositions pharmaceutiques les contenant | |
| CR20190261A (es) | Inhibidores de la tirosina quinasa de bruton | |
| MY169179A (en) | Novel piperidine compound or salt thereof | |
| HRP20100283T8 (hr) | Derivati n-'(1,5-difenil-1h-pirazol-3-il)sulfonamida s afinitetom za cb1 receptor | |
| RU2014121205A (ru) | Производные азолов | |
| AR121299A1 (es) | Inhibidores heterocíclicos de pad4 | |
| EA202191040A1 (ru) | Производные флаваглина для ингибирования активации онкогена kras | |
| AR049512A1 (es) | Derivados de tetrahidrofurano tetraciclicos. composiciones farmaceuticas | |
| EA200970793A1 (ru) | Модуляторы рецепторов, активируемых пролифераторами пероксисом | |
| PE20200756A1 (es) | Compuestos de indazol como potenciadores alostericos mglur4, composiciones y metodos de tratamiento de la disfuncion neurologica | |
| CY1111936T1 (el) | Ενωση κiνολονης και φαρμακευτικη συνθεση |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA | Abandonment or withdrawal |